Accelerating clinical trial readiness for shwachman diamond syndrome

Active Grant Awarded

Award ID
R01FD008823
Recipient
Awarding agency
Obligated
$599,999

Award facts

Assistance listing
93.103 Food and Drug Administration Research
Completion date 4% complete
Funding agency
Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

About this award

The U.S. Department of Health and Human Services Food and Drug Administration, through its Office of Medical Products and Tobacco, awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $599,999 obligated under Grant R01FD008823 on September 23, 2026. The award falls under Food and Drug Administration Research (CFDA 93.103), a program that supports research, demonstration, education, and information dissemination activities.

The project, titled "Accelerating Clinical Trial Readiness for Shwachman Diamond Syndrome," leverages the SDS Registry, a longitudinal natural history study that collects medical records and clinical samples for central data extraction and banking. The registry has established data standards, extraction protocols, oversight procedures, and expert adjudication. The recipient will use the registry and stakeholder partnerships to characterize the natural history of Shwachman Diamond Syndrome and address barriers to clinical trial readiness.

Performance runs from the award date through August 31, 2030, at Boston, MA 02115.

Description

Abstract
Shwachman diamond syndrome (SDS) is a rare genetic condition characterized by bone marrow failure, leukemia predisposition, and variable multi-organ system complications including the pancreas, liver, bones, and neurocognitive system. Biallelic mutations in the sbds gene account for around 90% of SDS cases. The sbds protein plays an important role in ribosome biogenesis. To advance our understanding of this rare condition, we established the SDS registry, a longitudinal natural history study of SDS powered by patients who share medical records and clinical samples for central data extraction and banking. The sdsr has established data standards, systematic data extraction protocols, data oversight procedures, and expert adjudication to ensure rigorous high- quality data, with nimble data field modifications in response to evolving diagnostic testing and treatments. We learned that the major cause of mortality is myeloid malignancy, which carries a very poor prognosis. Although advances have been made in hematopoietic stem cell transplant (HCT) for hematologic complications of SDS, HCT has limited efficacy against myeloid malignancy in SDS and poses substantial risks of organ toxicity which remain poorly characterized. Current clinical care focuses on longitudinal marrow surveillance to identify early clonal evolution and intervene with HCT before over malignancy develops. We and others have elucidated the molecular pathways driving malignancy in SDS, and molecular testing is integrated into surveillance; however, data on outcomes of molecular surveillance and preemptive transplants are limited. As preclinical studies for novel SDS therapies are rapidly advancing, there is a growing urgency to address barriers to clinical trial readiness. We will leverage the SDS registry and our partnerships with stakeholders to characterize the natural history of SDS, address emerging knowledge gaps driven by advances in clinical care and molecular diagnostics, incorporate stakeholder input to identify meaningful outcome measures and barriers to clinical trial participation, and apply advances in SDS biology to the development of biomarkers. Together, these studies will inform clinical trial design and endpoint selection, develop SDS-tailored pros for future clinical trials, enable the development of biological correlates to accelerate trial evaluation, address obstacles to therapeutic development, and provide well-curated data and biospecimen resources for the broader research community.

Quick answers

Who received award R01FD008823?

R01FD008823 was awarded to The Children's Hospital Corporation by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.

How much is award R01FD008823 worth?

$599,999 has been obligated on R01FD008823.

Which agency awarded R01FD008823?

FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD008823, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award